# CODA Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coda-genomics

- Industry: Biotechnology
- Headquarters: Laguna Hills, US
- Website: www.codagenomics.com
- Total disclosed funding: $9.2M
- Latest round: Series C (Jul 11, 2007)
- Investors on record: 5

## About

CODA Genomics delivers advanced gene synthesis solutions through its innovative CODA Gene Kits and CODExpress Gene Kits, empowering researchers in synthetic biology and protein production across the globe.CODA Genomics specializes in gene synthesis, providing products that enable researchers to construct and express synthetic genes. Founded in Laguna Hills, US, the company has remained focused on developing innovative solutions in the biotechnology sector. On July 11, 2007, CODA Genomics secured USD 7.000 mn in Series C funding, led by OVP Venture Partners, alongside participation from Monitor Ventures, Tech Coast Angels, and Life Science Angels. The total amount raised by the company stands at USD 7.000 mn.CODA Genomics specializes in gene synthesis solutions, primarily through its flagship offerings: CODA Gene Kits and CODExpress Gene Kits. These products enable researchers to assemble custom synthetic genes and express proteins with optimized constructs efficiently. CODA Gene Kits utilize advanced oligonucleotide assembly methods to ensure high-quality gene synthesis tailored to specific research needs, while CODExpress Gene Kits focus on accelerating custom protein expression, facilitating robust gene assembly, and achieving high protein yields. The company's solutions cater to a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies, by addressing challenges in synthetic biology and protein production. CODA Genomics serves a global customer base, with a significant presence in North America, Europe, and Asia, thereby enhancing research capabilities across various scientific fields.CODA Genomics operates primarily through a B2B model, providing its gene synthesis products to research institutions and commercial entities within the biotechnology and pharmaceutical sectors. The company’s revenue structure includes direct sales of CODA Gene Kits and CODExpress Gene Kits, which are packaged with pre-mixed oligonucleotides and reagents required for quick assembly. Customers typically engage in one-time purchases or repeat orders based on their ongoing research needs. Each product is designed to meet specific requirements, contributing to a reliable revenue stream based on the consistent demand for innovative synthetic biology solutions. The company's established reputation for advanced technology and high reliability enhances customer retention and positions CODA Genomics favorably in the competitive gene synthesis market.CODA Genomics plans to leverage its recent Series C financing of USD 7.000 mn, raised in July 2007, to enhance its product development efforts and expand its market presence. The company aims to introduce new gene synthesis products designed to meet emerging research needs over the next 18 months. Additionally, CODA Genomics is looking to enter new markets in Asia and Europe by the end of 2008, focusing on increasing its footprint in regions with growing biotechnology sectors. The funding will support these initiatives, aimed at strengthening its position and capabilities in gene synthesis.

## Funding rounds

- Series C, Jul 11, 2007, $7M — OVP Venture Partners, Monitor Ventures, Tech Coast Angels, Life Science Angels, Inc.
- Series B, Feb 28, 2006, $1.6M — Monitor Ventures, Tech Coast Angels, Life Science Angels, Inc.
- Series A, Jan 19, 2006, $0.6M — Seraphim Space Manager, Life Science Angels, Inc.

## Investors

- Seraphim Space Manager (https://capitalatlas.ai/funds/seraphim-space-manager) — Series A
- Life Science Angels, Inc. — Series A, Series B, Series C
- Monitor Ventures (https://capitalatlas.ai/funds/monitor-ventures) — Series B, Series C
- Tech Coast Angels — Series B, Series C
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series C